Editorial: Is CAR T‐Cell Therapy the Immunological Reset Autoimmunity Needs?

The advent of chimeric antigen receptor (CAR) T-cell therapy is redefining therapeutic boundaries in severe, treatment-refractory autoimmune diseases. Originally developed for hematologic malignancies, CAR T-cell therapy is now emerging as a transformative intervention for systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies, and systemic sclerosis. A comprehensive review by Chung et al. aptly synthesizes this evolving field and situates CAR T-cell therapy at the frontier of immune modulation in autoimmunity [1]. B-cell-directed therapies have long formed the cornerstone of treatment for many autoimmune conditions. However, agents such as rituximab, targeting CD20, achieve only partial B-cell depletion and are often insufficient in inducing sustained remission, especially in tissue-compartmentalized disease [1]. CAR T-cells targeting CD19—expressed across a broader B-cell lineage including plasmablasts—have demonstrated not only profound B-cell depletion but also rapid seroconversion and sustained drug-free remission in early clinical studies [2, 3]. Unlike monoclonal antibodies, CAR T-cells represent a living drug, with the capacity to traffic to inflamed sites and eliminate pathogenic cells with high efficiency. CAR T-cells differ fundamentally from passive antibody therapies. Once infused, they expand, persist, and actively target disease-driving B-cells, particularly in sanctuary sites that are often resistant to conventional therapies. Evidence from multiple studies indicates that anti-CD19 CAR T-cell infusion can induce rapid and profound B-cell aplasia, leading to seroconversion to autoantibody negativity and sustained clinical remission in conditions previously resistant to treatment [2, 3]. This durable therapeutic effect underpins the concept of immune reprogramming rather than suppression. The profound efficacy of this “living drug”, however, is matched by an equally profound need to understand its safety. Concerns regarding safety, particularly cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), persist. However, clinical data from autoimmune populations have thus far demonstrated a more favorable safety profile, potentially due to lower target burden and refined CAR constructs [1, 4]. Design modifications—such as incorporation of CD8α-derived hinge and transmembrane domains in place of CD28-derived motifs—have been shown to reduce pro-inflammatory cytokine release while preserving cytotoxic efficacy [5]. These engineering advances are essential for applying CAR T-cell therapy in non-malignant diseases, where the therapeutic margin must be wide. Nevertheless, vigilance is paramount. The long-term consequences of profound, albeit transient, B-cell depletion require systematic monitoring, and the potential for rare but serious toxicities cannot be dismissed. Efforts are also underway to extend the therapeutic reach beyond CD19. Given the persistence of CD19-negative long-lived plasma cells (LLPCs) in autoimmunity, dual-target CAR T-cells directed against both CD19 and B-cell maturation antigen (BCMA) have shown promising preliminary results in SLE [6]. Conversely, more selective approaches such as chimeric autoantibody receptor (CAAR) T-cells, which selectively target autoreactive B-cells via their cognate autoantigens, aim to preserve immune integrity but remain in early development [1, 7]. At present, broader depletion strategies appear to yield more reliable clinical benefit. Critical challenges remain. The requirement for lymphodepleting chemotherapy raises concerns regarding toxicity, fertility, and secondary malignancy risk. Trials are underway to assess reduced-intensity or non-myeloablative regimens. Furthermore, the durability of remission—potentially mediated by an immunological reset and reconstitution of a tolerant B-cell repertoire—must be clarified through long-term follow-up [1, 2, 8]. While early results are encouraging, the long preclinical phase of autoimmunity necessitates prolonged observation to determine whether true disease modification or cure has been achieved. The development of CAR-engineered regulatory T-cells (CAR-Tregs) introduces a novel concept: restoration of immune tolerance rather than cellular ablation [1]. These cells are designed not to eliminate targets, but to suppress inflammation and restore tissue-specific immune regulation. Although challenges remain in ensuring lineage stability and functional durability, this strategy offers a vision of future therapies focused on immune recalibration rather than deletion. In summary, CAR T-cell therapy represents a major leap forward in the treatment of refractory autoimmunity. Indeed, the seminal data from Müller et al. [3] has powerfully quantified this potential, demonstrating an unprecedented trifecta of outcomes: deep, durable remission, achieved in the absence of all other immunosuppressants, and with a remarkable safety profile (Figure 1). As clinical trials expand and mechanistic insights deepen, CAR T-cell therapies may fundamentally reshape the landscape of rheumatology, shifting the therapeutic goal from a lifetime of immunosuppression to the possibility of a lasting immunological peace. C.-Y.L. drafted the original manuscript. S.-B.Y., L.-C.S., and J.C.W. provided critical review and revised the manuscript. All authors read and approved the final manuscript. The authors have nothing to report. The authors declare no conflicts of interest. The authors have nothing to report.